New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2013
07:05 EDTSGMOSangamo presents clinical data from SB-728-T HIV studies
Sangamo's Phase 1 data suggested that if a threshold level of engraftment of SB-728-T was achieved, specifically of CD4 cells fully protected from HIV entry by zinc finger nuclease-mediated modification of both CCR5 genes, then functional control of HIV infection may be possible. New data from the SB-728-1101 study demonstrating a clear relationship between increasing the dose of Cytoxan and increased levels of both engrafted SB-728-T and total CD4 T-cell counts further support this hypothesis and suggest that with these, or higher doses, levels of SB-728-T that will enable functional control of the virus may be reliably attained.
News For SGMO From The Last 14 Days
Check below for free stories on SGMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SGMO

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use